OCEA (Ocean Biomedical) ROC %: -28.26% (As of Mar. 2025)

What is Ocean Biomedical ROC %?

Ocean Biomedical OCEA +100.00% ROC % is -28.26% as of Mar. 2025.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Ocean Biomedical's annualized return on capital (ROC %) for the quarter that ended in Mar. 2025 was -28.26%.

As of today (2026-06-25), Ocean Biomedical's WACC % is 0.00%. Ocean Biomedical's ROC % is 0.00% (calculated using TTM income statement data). Ocean Biomedical earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Ocean Biomedical (OTCPK:OCEA) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Ocean Biomedical's WACC % is 0.00%. Ocean Biomedical's ROC % is 0.00% (calculated using TTM income statement data). Ocean Biomedical earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Ocean Biomedical ROC % Related Terms

Ocean Biomedical ROC % Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical ROC % Chart

Ocean Biomedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROC %

Get a 7-Day Free Trial

0.00

-58.09

-29.82

-119.82

-22.51

Ocean Biomedical Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROC %	Get a 7-Day Free Trial															-16.01	-20.45	-20.68	-41.27	-28.26

Ocean Biomedical ROC % Calculation

Ocean Biomedical's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

	ROC % (A: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2023 )	+	Invested Capital (A: Dec. 2024 ))	/ count )
=	-3.798 * ( 1 - 0% )	/	( (16.273	+	17.479)	/ 2 )
=	-3.798	/	16.876
=	-22.51 %

where

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.501	-	17.131	-	( 0.004	-	max(0, 30.012	-	2.109	+	0.004	))
=	16.273

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.902	-	16.5	-	( 0	-	max(0, 33.889	-	0.812	+	0	))
=	17.479

Ocean Biomedical's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2025 is calculated as:

	ROC % (Q: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Mar. 2025 ))	/ count )
=	-3.832 * ( 1 - 0% )	/	( (17.479	+	9.638)	/ 2 )
=	-3.832	/	13.5585
=	-28.26 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.902	-	16.5	-	( 0	-	max(0, 33.889	-	0.812	+	0	))
=	17.479

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.582	-	17.02	-	( 0	-	max(0, 26.568	-	1.492	+	0	))
=	9.638

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -28.26% mean?

Ocean Biomedical (OCEA) has a ROC % of -28.26% as of Mar. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Ocean Biomedical and its competitors.

Is Ocean Biomedical's ROC % too high?

Ocean Biomedical's current ROC % is -28.26%.

How does Ocean Biomedical's ROC % compare to SIGY and ENDV?

Ocean Biomedical's ROC % of -28.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Ocean Biomedical and its competitors. Ocean Biomedical's current ROC % is -28.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ocean Biomedical stock overvalued right now?

Ocean Biomedical (OCEA) has a current ROC % of -28.26%. The current ROC % is -28.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current ROC % is -28.26% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Industry Healthcare Biotechnology

Comparable Companies SIGY ENDV SCPX RGBP CNBX WINT VINC HEPA ATXI RMTG VRTX REGN XBRU:UCB XKRX:207940 XBRU:ARGX ASX:CSL ALNY ONC XKRX:068270 INSM

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903

Website https://www.oceanbiomedical.com

Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.